In this interview, Ardeshir (Art) Rastinehad, DO, discusses the current state of focal therapy in prostate cancer, the role of fusion biopsy in pushing the treatment forward, and what institutions looking to implement focal therapy should know.
In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting.
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Sarah P. Psutka, MD, MSc, shares the rationale for the “Get Moving Trial,” exploring at-home prehabilitation for patients with muscle-invasive bladder cancer.
UGN-101 showed efficacy in a broad population of patients with upper tract urothelial cancer and recurrence-free survival rates were high among patients who responded to…
“So, in the MoonRISe-1 study, we’re studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every…
Patients receiving PUL experienced improvements of 8.6 and (39.1%) and 10 (46.8%) in IPSS total score.
